Active Recombinant Full Length Human CDK8 Protein, GST-tagged

• Cat.No.: CDK8-2151HF
• Product Overview: Full-length human CDK8 [1-464(end) amino acids of accession number NP_001251.1] was co-expressed as N-terminal GST-fusion protein (80 kDa) with human GST-CyclinC [1-283(end) amino acids of accession number NP_005181.2] using baculovirus expression system. GST-CDK8/CycC was purified by using glutathione sepharose chromatography.

Specification

• Source: Insect (sf21)
• Species: Human
• Tag: GST
• Form: 50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% glycerol, pH7.5
• Bio-activity: The activity was determined by ELISA. The enzyme was incubated with biotinylated peptide in streptavidin-coated ELISA plate. Phosphorylation was detected by anti-phospho antibody and HRP- labeled anti-rabbit IgG(or HRP-labeled anti-mouse IgG).
• Protein length: 1-464(end)
• Purity: 94%
• Applications: SDS-PAGE
• Storage: Store at -80C. Avoid repeating freeze-thaws.

Gene Information

• Gene Name: cyclin-dependent kinase 8
• Official Symbol: CDK8
• Synonyms: CDK8;IDDHBA;K35
• Protein Refseq: NP_001251.1
• UniProt ID: P49336

Reviews

03/05/2020

The CDK8 protein stands as a remarkable solution that exemplifies exceptional quality and meets all my experimental requirements.

08/03/2019

I am confident that the CDK8 protein will unlock vital insights into cellular processes, propelling my scientific investigations to new heights.

10/01/2017

Its impressive purity and functional characteristics make it an ideal choice for my research endeavors, ensuring reliable and impactful results.

Q&As

Is CDK8 exclusively associated with cancer, or does it have physiological roles in normal cellular functions?

CDK8 plays essential roles in normal cellular functions, including development and tissue homeostasis. Its dysregulation, however, is implicated in cancer.

Can CDK8 inhibitors be used in combination with other cancer treatments, and if so, what are the potential benefits?

Combination therapies involving CDK8 inhibitors are being explored to enhance treatment outcomes and reduce the likelihood of resistance, providing a more comprehensive approach to cancer management.

How does CDK8 inhibition affect the cell cycle, and why is this significant in cancer therapy?

CDK8 inhibition can disrupt the cell cycle, slowing down or halting the uncontrolled cell division characteristic of cancer cells, making it a potential therapeutic strategy.

How does CDK8 influence the immune response in the tumor microenvironment?

CDK8 can modulate the expression of genes involved in immune response. Understanding its role in the tumor microenvironment may lead to novel immunotherapeutic strategies.

Are there ongoing clinical trials investigating the efficacy of CDK8 inhibitors in cancer patients?

Yes, several clinical trials are underway to assess the safety and effectiveness of CDK8 inhibitors as a targeted therapy for different types of cancer.